All In Biotech

Free tool

FAERS Monitor: Herceptin Hylecta

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 761106 or its brand name (Herceptin Hylecta, Trastuzumab and Hyaluronidase-Oysk). Reports on generic versions are filed under their own applications.

Reports

107

Serious

25

23% of reports

Hospitalization

6

Death reported

3

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • no adverse event30
  • off label use23
  • injection site pain8
  • diarrhoea7
  • product storage error7
  • nausea6
  • pain6
  • neuropathy peripheral5
  • death4
  • fatigue4
  • intentional product use issue4
  • product administered at inappropriate site4
  • stomatitis4
  • weight decreased4
  • alopecia3

Reports by year received

View as table
YearReports
20196
202012
202116
202217
20239
202421
202515
202611

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,052 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
product administered at inappropriate siteSignal442.916.4125
no adverse eventSignal3032.624.0894
product storage errorSignal715.77.783
stomatitisSignal413.05.033
neuropathy peripheralSignal510.34.433
intentional product use issueSignal49.03.421
off label useSignal235.23.676
injection site painSignal85.12.623
alopecia33.01.02
weight decreased42.81.13
diarrhoea72.11.03
pain61.90.92
nausea61.50.71
fatigue41.00.40
death40.90.30

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.